Dipyridamole potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in mice

Parkinsonism and Related Disorders

Volumn 4, Issue 1, 1998, Pages 43-50

  Tariq, Mohammad ^a   Khan, Haseeb A ^a   Al Moutaery, Khalaf ^a   Al Deeb, Saleh ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

Adenosine; Behavioral effects; Dipyridamole; Dopamine; Glutathione; MPTP; Parkinsonism; Vitamin E

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE; DIPYRIDAMOLE; DOPAMINE; GLUTATHIONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; INCIDENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NERVE CELL EXCITABILITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032104545     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(98)00007-8     Document Type: Article

References (76)

1. [1] Ballard PA, Tetrud JW, Langston JW. Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology, 1985;35:949-956.
2. [2] Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res, 1984;292:390-394.
3. -): identification of a metabolite of MPTP, a toxin to the substantia nigra. Neurosci Lett, 1984;48:87-92.
4. [4] Chiba K, Trevor AJ, Castagnoli N Jr. Metabolism of the neurotoxin tertiary amine MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun, 1984;120:574-578.
5. [5] Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-melhyl-4-phenyl-1,2,3,6-tetra-hydropyridine, Life Sci, 1985;36:2503-2508.
6. [6] Chiueh CC, Wu RM, Mohankumar KP, Sternberger LM, Krishna G, Obata T, Murphy DL. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci, 1994;738:25-36.
7. +) induces oxidative stress in the rodent. Life Sci, 1985;38:743-749.
8. [8] Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 1984;311:467-469.
9. [9] Szirakin I, Kardos V, Patthy M, Patfelusi M, Budai G. Methamphetamine protects against MPTP neurotoxicity in C57 BL mice. Eur J Pharmacol, 1994;251:311-314.
10. [10] Gerlach M, Russ H, Winker J, Witzmann K, Traber J, Stasch JD, Riedener P, Przuntek H. Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice. Arzneimittelforschung, 1993;43:413-415.
11. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 1991;349:414-418.
12. [12] Jones-Humble SA, Morgan PF, Cooper BR. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci, 1994;54:245-252.
13. [13] Kitamura Y, Itano Y, Kubo T, Nomura Y. Suppressive effect of FK506, a novel immunosuppressant against MPTP-induced dopaminergic depletion in the striatum of young C57 BL/6 mice. J Neuroimmunol, 1994;50:221-224.
14. [14] Schulz JB, Matthews RT, Mugit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem, 1995;64:936-939.
15. [15] Heo JH, Kim DG, Bahny HR, Kim JS. Dimethylthiourea prevents MPTP-induced decrease in [3H] dopamine uptake in rat striatal slices. Brain Res, 1995;671:321-324.
16. [16] Oishi T, Hasegawa E, Murai Y. Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. J Neural Transm, 1993;6:45-52.
17. +-induced oxidative injury by deprenyl (selegiline), U-78517 f, and DMSO. New Trends Clin Neuropharm, 1994;8:187-188.
18. [18] Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff NH. Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J Pharmacol Exp Ther, 1994;270:639-644.
19. [19] Chan P, Langston W, Irwin I, De Lanney LE, Di Monte DA. 2-Deoxy glucose enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse brain. J Neurochem, 1993;61:610-616.
20. [20] Behmand RA, Harik SI. Nicotine enhances 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine neurotoxicity. J Neurochem, 1992;58:776-779.
21. 2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull, 1993;34:397-404.
22. [22] Mally J, Stone TW. The effect of theophylline on Parkinsonian symptoms. J Pharm Pharmacol, 1994;46:515-517.
23. [23] Phillis JW, Wu PH. The role of adenosine and its nucleotides in central synaptic transmission. Prog Neurobiol, 1981;16:187-239.
24. [24] Williams M. Purine receptors in mammalian tissues: pharmacology and functional significance. Ann Rev Pharmacol Toxicol, 1987;27:315-345.
25. [25] Berne RM, Rubio R, Curnish RR. Release of adenosine from ischemic brain. Effect of cerebral vascular resistance and incorporation into cerebral adenosine nucleotides. Circ Res, 1974;35:262-271.
26. [26] Shultz V, Lowenstein JM. The purine nucleotide cycle. J Biol Chem, 1978;253:1938-1943.
27. [27] Winn HR, Bowe AB, Welsh JE, Rubio R, Berne RM. Changes in adenosine during sustained hypoxia. In: Goton F, Nagai H, Tazaki Y, editors. Cerebral blood flow and metabolism. Copenhagen: Munksgaard, 1979:330-1.
28. [28] Marangos PJ, Miller L. Adenosine-based therapeutics in neurologic disease. In Philhs JW, editor. Adenosine and adenine nucleotides as regulators of cellular function. Boca Raton, FL: CRC Press, 1991:413-22.
29. [29] Fitz-Gerald GA. Dipyridamole. N Engl J Med. 1987;312:1247-1257.
30. [30] Park TS, Gidday JM. Effect of dipyridamole on cerebral extracellular adenosme levels in vivo. J Cereb Blood Flow Metab, 1990;10:424-427.
31. [31] Sollevi A. Cardiovascular effects of adenosine in man: possible clinical implications. Prog Neurobiol, 1986;27:319-349.
32. [32] Parkinson FE, Fredholm BB. Effect of propentofylline on adenosine A1 and A2 receptors and nitrobenzylthioinosine-sensitive nucleoside transporters: quantitative autoradiographic analysis. Eur J Pharmacol, 1991;202:361-366.
33. [33] Tariq M, Al Deeb S, Al Moutaery K, Bruyn GW, Price Evans DA, Arshaduddin M. Dipyridamole attenuates the development of iminodipropionitrile-induced dyskinetic abnormalities in rats. Brain Res Bull, 1995;38:31-35.
34. [34] Tariq M, Aqeel MA. Gastric antiulcer and cytoprotective effects of dipyridamole in rats. J Pharmacol Exp Ther, 1990;253:944-949.
35. [35] Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y. MPTP-induced Parkinsonism model in mice: biochemistry, pharmacology and behavior. Eur Neurol, 1987;26:16-23.
36. [36] Patrick OE, Hirohisa M, Masahiro K, Koreaki M. Central nervous system bioaminergic responses to mechanic trauma. Surg Neurol, 1991;35:273-279.
37. [37] Owen WG. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem, 1980;106:207-212.
38. [38] Meydani M, Evans WJ, Handelman G, Biddle L, Fielding RA, Meydani SN, Burrill J, Fiatarone MA, Blumberg JB, Cannon JG. Protective effect of vitamin E on exercise-induced oxidative damage in young and older-adults. Am J Physiol, 1993;264:R992-R998.
39. [39] Davis CG, Williams AG, Markey SP, Ebert MH, Caine ED. Reichert CM, Kopin IJ. Chronic parkinsonism secondary to intravenous injection of meperidine. Psychiatr Res. 1979;1:249-254.
40. [40] Miller DB, Reinhard JF Jr, Daniels AJ, O'Callaghan JP. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and in vitro 1-methyl-4-phenylpyridinium. J Neurochem, 1991;57:541-549.
41. [41] Phillis JW, Wu PH. Adenosine mediates sedative action of various centrally active drugs. Med Hypoth, 1982;9:361-367.
42. [42] Marks JD, Donnely FD, Haddad GG. Adenosine-induced inhibition of vagal motoneuron excitability: Receptor subtype and mechanism. Am J Physiol, 1993;264:L124-L132.
43. [43] Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci USA, 1981;78:3260-3264.
44. [44] Coffin VL, Carney JM. Behavioral pharmacology of adenosine analogs. In Daly J, Kuroda Y, Phillis J, Ui M, editors. Physiology and pharmacology of adenosine derivatives. New York: Raven Press, 1983:267-74.
45. 2 receptors via intramembrane receptor-receptor interactions. Relevance for Parkinson's disease and schizophrenia. Neurochem Int, 1992;20:215S-224S.
46. [46] Porter NM, Raduloracki M, Green RD. Desensitization of adenosine and dopamine receptors in rat brain after treatment with adenosine analogs. J Pharmacol Exp Ther, 1988;244:218-225.
47. [47] Rudolphi KA, Schubert P, Parkinson EE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci, 1992;13:439-445.
48. [48] Boissard CG, Gribkoff VK. The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CAI of rat hippocampus in vitro. Neuropharmacology, 1993;32:149-155.
49. [49] Fowler JC. Changes in extracellular adenosine levels and population spike amplitude during graded hypoxia in the rat hippocampal slice. Naunyn-Schmideberg's Arch Pharmacol, 1993;347:73-78.
50. [50] Kawagoe J, Abe K, Ikuta J, Igarashi N, Shimizu S, Yamauchi Y, Kogure K. Effect of dilazep dihydrochloride against ischaemia and reperfusion-induced disruption of blood-brain barrier in rats: a quantitative study. Naunyn-Schmiedeberg's Arch Pharmacol, 1992;345:485-488.
51. 1 receptor agonist or antagonist in cerebral ischaemia. Eur J Pharmacol, 1994;256:161-167.
52. 1) receptor by caffeine treatment. Neurosci Lett, 1989;103:275-280.
53. [53] Dragunow M. Adenosine and epileptic seizures. In: Phillis JW, editor. Adenosine and adenine neucleotides as regulators of cellular function. Boca Raton, FL: CRC Press, 1991:367-79.
54. 1 receptor number. Brain Res, 1993;612:271-277.
55. [55] Georgiev V, Johansson B, Kuosmanen T, Fredholm BB. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline-and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur J Neurosci, 1996;8:2447-2458.
56. [56] Jacobson KA, von Lubitz DKJE, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute chronic treatment. Trends Pharmacol Sci, 1996;17:108-113.
57. [57] Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature, 1994;311:464-467.
58. [58] Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett, 1989;48:121-149.
59. [59] Ramsey RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondria. J Biol Chem, 1986;261:7585-7587.
60. [60] Westernik BHC, Damsma G, Rollemah H, De Vries JB, Horn AS. Scope and limitations of in vivo brain dialysis: a comparison of its applications to various neurotransmitter systems. Life Sci, 1987;41:1763-1776.
61. [61] Chan P, Di Monte DA, Luo JJ, De Lanney LE, Irwin I, Langston JW. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem, 1994;62:2484-2487.
62. [62] Ossowska K. The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm Park Dis Dement Sect, 1994;8:39-71.
63. + neurotoxicity by N-methyl-D-aspartate antagonists. Brain Res, 1992;586:203-207.
64. [64] Tabatabaei A, Perry TL, Hansen S, Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci Lett, 1992;141:192-194.
65. [65] Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinsonism in primates. J Neurochem, 1992;59:733-739.
66. [66] Rothman SM. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci, 1984;4:1884-1891.
67. [67] Weiss J, Goldberg MP, Choi D. Ketamine protects cultured neocortical neurons from hypoxic injury. Brain Res, 1986;380:186-190.
68. [68] Lobner D, Choi DW. Dipyridamole increases oxygen-glucose deprivation-induced injury in cortical cell culture. Stroke, 1994;25:2085-2089.
69. [69] Przedborski S, Kosti V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL. Transgenic mice with increase Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci, 1992;12:1658-1667.
70. [70] Scotcher KP, Irwin I, Delanney LE, Langston JW, Di Monte D. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl pyridinium ion on ATP levels of mouse brain synaptosomes. J Neurochem, 1990;54:1295-1301.
71. [71] Basma AN, Heikkila RE, Saporito MS, Philbert M, Geller HM, Nicklas WJ. 1-Methyl-4-(2′-ethyl phenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis. J Neurochem, 1992;58:1052-1059.
72. [72] Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinsons disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol, 1994;36:348-355.
73. [73] Dexter D, Carter C, Agid F, Lees AJ, Jenner P, Marsden CD. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. The Lancet 1986;2:639-640.
74. + administration to mice. Pharmacol Toxicol, 1993;72:364-368.
75. [75] Odunze IN, Klaidman LK, Adams JD Jr. MPTP toxicity in the mouse brain and vitamin E. Neurosci Lett, 1990;108:346-349.
76. [76] Chi DS, Gong L, Daigneault EA, Kostezewa RM. Effects of MPTP and vitamin E treatment on immune function in mice. Int J Immunopharmacol, 1992;14:739-746.